Understanding different types of insulin resistance and their effects on triglyceride levels
Metabolic heterogeneity underlying hypertriglyceridemia in insulin resistance
This study is looking at how insulin resistance affects triglyceride levels in different people, with the goal of finding personalized treatments that work best for each individual.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10800703 on NIH RePORTER |
What this research studies
This research investigates how insulin resistance varies among patients and how these differences affect their triglyceride levels. By using a precision medicine approach, the study aims to identify specific mechanisms that lead to increased triglyceride production in individuals based on their unique patterns of insulin resistance. The research involves examining rodent models to understand the pathways that contribute to fat production in the liver and how these pathways differ in patients with varying types of insulin resistance. Ultimately, the goal is to tailor therapies to better suit individual patients' needs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with insulin resistance or type 2 diabetes, particularly those experiencing high triglyceride levels.
Not a fit: Patients without insulin resistance or those who do not have issues with triglyceride levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with insulin resistance and high triglyceride levels, potentially reducing their risk of developing type 2 diabetes.
How similar studies have performed: Previous research has shown promise in using precision medicine approaches to tailor treatments for metabolic diseases, indicating that this study builds on established concepts.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Vatner, Daniel — Yale University
- Study coordinator: Vatner, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.